421 related articles for article (PubMed ID: 11859400)
21. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
Aurelius E; Franzen-Röhl E; Glimåker M; Akre O; Grillner L; Jorup-Rönström C; Studahl M;
Clin Infect Dis; 2012 May; 54(9):1304-13. PubMed ID: 22460966
[TBL] [Abstract][Full Text] [Related]
22. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
[TBL] [Abstract][Full Text] [Related]
24. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
Warren T; Harris J; Brennan CA
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
[TBL] [Abstract][Full Text] [Related]
26. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children.
Nadal D; Leverger G; Sokal EM; Floret D; Perel Y; Leibundgut K; Weller S
J Infect Dis; 2002 Oct; 186 Suppl 1():S123-30. PubMed ID: 12353197
[TBL] [Abstract][Full Text] [Related]
27. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
Fiddian P; Sabin CA; Griffiths PD
J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
[TBL] [Abstract][Full Text] [Related]
28. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens.
Gilbert S; McBurney E
Dermatol Surg; 2000 Jan; 26(1):50-4. PubMed ID: 10632686
[TBL] [Abstract][Full Text] [Related]
29. Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients.
Kim JH; Schaenman JM; Ho DY; Brown JM
Biol Blood Marrow Transplant; 2011 Feb; 17(2):259-64. PubMed ID: 20615475
[TBL] [Abstract][Full Text] [Related]
30. Valacyclovir in the treatment of facial herpes simplex virus infection.
Laiskonis A; Thune T; Neldam S; Hiltunen-Back E
J Infect Dis; 2002 Oct; 186 Suppl 1():S66-70. PubMed ID: 12353189
[TBL] [Abstract][Full Text] [Related]
31. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease.
Erard V; Wald A; Corey L; Leisenring WM; Boeckh M
J Infect Dis; 2007 Jul; 196(2):266-70. PubMed ID: 17570114
[TBL] [Abstract][Full Text] [Related]
32. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
33. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
35. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection.
Bras AP; Sitar DS; Aoki FY
Can J Clin Pharmacol; 2001; 8(4):207-11. PubMed ID: 11743593
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of safety and efficacy of prolonged suppressive therapy of genital herpes with valacyclovir.
Durglishvili N; Shishniashvili D; Kvirkvelia V
Georgian Med News; 2009; (172-173):47-9. PubMed ID: 19644189
[TBL] [Abstract][Full Text] [Related]
37. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
38. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment.
Leone PA; Trottier S; Miller JM
Clin Infect Dis; 2002 Apr; 34(7):958-62. PubMed ID: 11880962
[TBL] [Abstract][Full Text] [Related]
39. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic valacyclovir to prevent outbreaks of primary herpes gladiatorum at a 28-day wrestling camp.
Anderson BJ
Jpn J Infect Dis; 2006 Feb; 59(1):6-9. PubMed ID: 16495626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
